Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria

被引:35
作者
Winstanley, P [1 ]
机构
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England
关键词
falciparium malaria; drug development; LAPDAP;
D O I
10.1046/j.1365-3156.2001.00751.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The synergistic antifolate combination of chlorproguanil with dapsone (CPG-DDS; LAPDAP) is being developed by a public-private partnership as a low-cost treatment for uncomplicated falciparum malaria. LAPDAP is rapidly eliminated from the body, giving it low selection pressure for drug resistance. Clinical cases with sulphadoxine-pyrimethamine (SP)-resistant infections acquired in Africa have been predicted to be responsive to LAPDAP, and clinical evidence is available to support this. A regulatory dossier is being prepared for simultaneous submission to the UK Medicines Control Agency and African licencing authorities. The team working on LAPDAP has also started to develop the triple combination of chlorproguanil-dapsone-artesunate (CDA) as a low-cost combination therapy for uncomplicated falciparum malaria. Although LAPDAP does not have regulatory approval (and development of CDA is at an early stage), the development team is keen to communicate with public health scientists to try to anticipate the policy and implementation hurdles that lie ahead. This short paper outlines the current stages that LAPDAP and CDA have reached, and sketches the anticipated public health issues.
引用
收藏
页码:952 / 954
页数:3
相关论文
共 10 条
  • [1] Chlorproguanil-dapsone: Effective treatment for uncomplicated falciparum malaria
    Amukoye, E
    Winstanley, PA
    Watkins, WM
    Snow, RW
    Hatcher, J
    Mosobo, M
    Ngumbao, E
    Lowe, B
    Ton, M
    Minyiri, G
    Marsh, K
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) : 2261 - 2264
  • [2] MUTABINGWA T, 2001, IN PRESS LANCET
  • [3] Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethaminel/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum
    Nzila, AM
    Nduati, E
    Mberu, EK
    Sibley, CH
    Monks, SA
    Winstanley, PA
    Watkins, WM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (06) : 2023 - 2028
  • [4] Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum:: Genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites
    Nzila, AM
    Mberu, EK
    Sulo, J
    Dayo, H
    Winstanley, PA
    Sibley, CH
    Watkins, WM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) : 991 - 996
  • [5] TREATMENT OF PLASMODIUM-FALCIPARUM MALARIA WITH PYRIMETHAMINE-SULFADOXINE - SELECTIVE PRESSURE FOR RESISTANCE IS A FUNCTION OF LONG ELIMINATION HALF-LIFE
    WATKINS, WM
    MOSOBO, M
    [J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1993, 87 (01) : 75 - 78
  • [6] The efficacy of antifolate antimalarial combinations in Africa: A predictive model based on pharmacodynamic and pharmacokinetic analyses
    Watkins, WM
    Mberu, EK
    Winstanley, PA
    Plowe, CV
    [J]. PARASITOLOGY TODAY, 1997, 13 (12): : 459 - 464
  • [7] Preventing antimalarial drug resistance through combinations
    White, NJ
    [J]. DRUG RESISTANCE UPDATES, 1998, 1 (01) : 3 - 9
  • [8] Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: Pharmacokinetics and therapeutic range
    Winstanley, P
    Watkins, W
    Muhia, D
    Szwandt, S
    Amukoye, E
    Marsh, K
    [J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1997, 91 (03) : 322 - 327
  • [9] IN-VITRO ACTIVITIES OF NOVEL ANTIFOLATE DRUG-COMBINATIONS AGAINST PLASMODIUM-FALCIPARUM AND HUMAN GRANULOCYTE CFU-S
    WINSTANLEY, PA
    MBERU, EK
    SZWANDT, ISF
    BRECKENRIDGE, AM
    WATKINS, WM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (04) : 948 - 952
  • [10] Chemotherapy for falciparum malaria: The armoury, the problems and the prospects
    Winstanley, PA
    [J]. PARASITOLOGY TODAY, 2000, 16 (04): : 146 - 153